CTLA4 and neoplasm: The POC of ICI, i.e., anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies, which reverse cancer immunosuppression and promote anti-tumor immune responses in several cancer types, were first demonstrated by using these mouse models8.